Why the first 16 weeks look slow
The most common reason people feel discouraged early is that they are comparing a titration-phase result to a full-dose result. Semaglutide prescribed for weight management starts at 0.25 mg once weekly and steps up every four weeks through 0.5, 1.0, and 1.7 mg before reaching the 2.4 mg maintenance dose at week 16, according to prescribing information reviewed in the StatPearls semaglutide reference on NIH. During those early weeks the appetite suppression effect is partial, and the low starting doses are deliberately chosen to reduce nausea and side effects, not to maximize weight loss.
Some of the weight that drops in the first two to four weeks is also water weight tied to glycogen depletion. When food intake falls, the body burns stored carbohydrate (glycogen), and each gram of glycogen holds roughly three grams of water. The scale can look dramatic, then appear to stall as that water loss stabilizes before meaningful fat loss accelerates.
In a real-world analysis of outcomes in patients prescribed FDA-approved injectable semaglutide (Wegovy or Ozempic), published in BMC Endocrine Disorders, patients at 12 weeks had lost roughly 6 percent of body weight, and by 28 weeks roughly 12 percent. This is data from a population treated with an FDA-approved semaglutide product; compounded semaglutide is not FDA-approved and has not been evaluated in equivalent clinical trials. If the dose has not yet reached its target, expecting peak results is premature.
Trial averages hide wide individual differences
When the average weight loss figure from the STEP 1 trial is repeated often, it can start to feel like a personal target. It is not. Trial averages summarize a distribution, and that distribution was wide even among people who received the same drug at the same dose.
In the STEP 1 randomized, placebo-controlled trial of Wegovy (semaglutide 2.4 mg) in adults with overweight or obesity, published in the New England Journal of Medicine, the mean body weight change at 68 weeks was 14.9 percent in the semaglutide group. Eighty-six percent of semaglutide participants lost 5 percent or more of their baseline body weight, which means roughly 14 percent did not reach that threshold despite completing the trial.
Biology accounts for most of this variation. Genetics affecting GLP-1 receptor sensitivity, degree of insulin resistance, gut microbiome composition, and hypothalamic responsiveness all contribute. None of these factors appear on a scale reading. Being a below-average responder in a clinical trial does not mean a person cannot lose meaningful weight; it means the current protocol may need review. Compounded semaglutide is not FDA-approved and has not been studied in trials comparable to STEP 1, so responder data specific to compounded formulations are not available.
Plateaus are built into the biology of weight loss
A plateau that appears after months of steady progress is not a sign that semaglutide has stopped working. It reflects how the body responds to any sustained caloric deficit, and it occurs with all forms of weight loss, not just GLP-1 therapy.
Research tracking prolonged treatment with FDA-approved semaglutide in human subjects, published in PMC in 2025, identified three distinct phases of GLP-1-induced weight loss: a rapid early phase driven primarily by reduced food intake, a slower gradual loss phase in which food intake begins returning toward baseline as appetite adapts, and a maintenance plateau. During the gradual phase, compensatory metabolic adaptations start to close the caloric gap even when the medication is still present and active.
The body also reduces its resting metabolic rate as it becomes lighter, a process called adaptive thermogenesis. A smaller body burns fewer calories at rest than a larger one, so the same diet that once produced a deficit eventually produces a smaller one. The STEP 5 two-year trial of Wegovy (semaglutide 2.4 mg), published in Nature Medicine, showed participants continuing to lose weight through roughly 60 weeks before reaching a stable plateau, with a mean total weight reduction of 15.2 percent at two years. A plateau within the first year, while frustrating, often has room to move with the right adjustments. Compounded semaglutide is not FDA-approved and has not been evaluated over equivalent timeframes in controlled trials.
Low protein intake accelerates a stall
When appetite drops sharply on semaglutide, the calories that are eaten matter more, not less. A joint advisory from the Obesity Medicine Association, the American Society for Nutrition, the American College of Lifestyle Medicine, and the Obesity Society, published in Obesity Pillars, found that GLP-1 receptor agonist treatment reduces caloric intake by 16 to 39 percent. At those reductions, protein intake can fall sharply unless it is actively prioritized at every meal.
The consequences show up on the scale in the wrong way. Analysis cited in the same advisory found that in the STEP 1 trial of Wegovy (semaglutide 2.4 mg), approximately 38 percent of the average 13.6 kg weight reduction was lean body mass (roughly 5.3 kg), not fat tissue. Losing muscle mass lowers the resting metabolic rate further, which moves the plateau earlier and makes it harder to break. This data is from an FDA-approved drug trial; compounded semaglutide is not FDA-approved and has not been evaluated in equivalent body composition studies.
The same advisory recommends a protein target of 1.2 to 1.6 grams per kilogram of adjusted body weight per day during active weight loss, or roughly 80 to 120 grams daily as a practical target. Pairing adequate protein with structured resistance training at least two to three times per week is the strategy most supported by the evidence for preserving muscle during GLP-1-assisted weight loss. A registered dietitian can help set a target based on individual factors.
Liquid calories and alcohol are the easy miss
Semaglutide suppresses appetite for solid food more reliably than it filters out liquid calories. Sweetened coffee drinks, fruit juices, flavored sparkling waters with sugar, protein shakes with added sweeteners, and alcohol all contribute meaningful calories without triggering the same satiety signals that an equivalent amount of solid food would. A single large flavored latte can carry 300 to 400 calories that most people do not mentally register as a meal.
Alcohol deserves particular attention. Ethanol contains 7 calories per gram, more than protein or carbohydrate (4 cal/g each) and close to fat (9 cal/g). Alcohol also pauses fat oxidation: the liver prioritizes clearing ethanol before burning stored fat, which can directly extend a weight stall. A 2023 observational study published in PubMed found that semaglutide and tirzepatide reduced self-reported alcohol consumption for many users, including fewer binge drinking episodes, but this effect was not universal. People who did not naturally reduce their intake did not benefit from this mechanism.
Tracking all beverages honestly for one week, including exact amounts of alcohol, often reveals a calorie gap that explains a stall that lifestyle audits otherwise miss. A clinician or dietitian can help assess the impact on the overall energy balance. For a closer look at how drinking affects outcomes, see whether you can drink alcohol while taking semaglutide.
Sleep and stress push weight loss in reverse
Poor sleep raises cortisol and increases ghrelin, the hormone that signals hunger. These hormonal shifts push appetite back up and can partly undo the appetite suppression that makes semaglutide effective. When sleep is short or fragmented, the brain's reward response to food also increases, making it harder to resist calorie-dense choices even when someone is motivated to eat well.
A 2025 observational study of patients using oral GLP-1 receptor agonists, published in BMC Nutrition, found that sleeping more than six hours per night was strongly protective against treatment failure. Participants who extended their sleep past six hours showed an odds ratio of 0.15 for failing to achieve their weight loss goal, meaning they were far more likely to succeed than shorter sleepers. At baseline, 31.3 percent of participants in that study were sleeping fewer than six hours per night. This study was conducted in patients prescribed oral GLP-1 receptor agonists, which are a different formulation from injectable semaglutide; whether the same association holds specifically for injectable semaglutide has not been confirmed in equivalent studies. Compounded semaglutide is not FDA-approved and has not been evaluated in studies of this kind.
Late eating patterns added another independent risk: meals after 9 PM with less than three hours between dinner and sleep significantly reduced outcomes, likely through circadian disruption of glucose metabolism. Addressing sleep is a low-cost, evidence-supported step that most plateau audits skip. A healthcare provider can also evaluate whether underlying conditions such as obstructive sleep apnea are contributing, since sleep apnea is more common in people with obesity and often goes undiagnosed for years.
Medications that work against weight loss
Several common prescription medications promote weight gain or directly counteract the caloric deficit that drives weight loss. They do not neutralize semaglutide entirely, but they create an uphill climb that can make even an optimized protocol look like a failure when the real problem is a prescribing interaction.
A comprehensive review published in PMC identified the main categories: atypical antipsychotics (olanzapine, clozapine, quetiapine, risperidone), certain antidepressants (paroxetine, mirtazapine), corticosteroids such as prednisone taken regularly, insulin and some insulin secretagogues, certain beta-blockers (particularly atenolol and metoprolol), and some antihistamines and anticonvulsants. The weight-promoting effect varies from a few pounds to more than 20 pounds per year depending on the drug, dose, and individual.
The right response is never to stop a prescribed medication without provider guidance. Instead, this is worth raising directly at the next appointment: "Are any of my current medications contributing to weight gain?" In some cases a clinician can substitute a weight-neutral or weight-negative alternative within the same drug class. In other cases the medication cannot be changed and expectations need to be adjusted. Knowing the answer prevents months of unnecessary frustration and keeps the treatment plan grounded in the full clinical picture.
A practical audit before the next appointment
The table below summarizes the seven most common modifiable reasons for a stall. Working through each one honestly before a provider visit turns a frustrating conversation into a productive one.
| Factor to audit | Common pitfall | Action step |
|---|---|---|
| Dose and titration | Still in titration phase; comparing to full-dose trial results | Confirm current dose and how long at this dose with your prescriber |
| Protein intake | Eating far less overall but not protecting protein; muscle lost with fat | Aim for 1.2 to 1.6 g per kg per day; prioritize protein at every meal |
| Liquid calories | Underestimating coffees, juices, flavored drinks, and protein shakes | Log all beverages for one week and total the calories |
| Alcohol | Food appetite suppressed but alcohol intake unchanged; 7 cal/g not counted | Reduce or eliminate alcohol; track units consumed per week |
| Sleep | Under 6 hours per night raises cortisol and ghrelin, increasing hunger | Target 7 to 9 hours; ask provider to screen for sleep apnea |
| Chronic stress | Elevated cortisol from sustained stress increases appetite and fat storage | Identify primary stressors; consider structured stress management |
| Concurrent medications | Taking a weight-promoting medication without knowing its effect | Bring a full medication list to your provider and ask about weight effects |
Talking to your provider about dose and next steps
When someone has been at a stable dose for 12 or more weeks and has lost less than 5 percent of their starting body weight, that meets the clinical threshold most guidelines use to trigger a formal reassessment. A post-hoc analysis of STEP 4 data for Wegovy (semaglutide 2.4 mg), published in PMC, confirmed that early response at 12 weeks does not reliably predict long-term success, supporting the idea that the 12-week mark is a decision point for review, not a final verdict on the medication.
A provider visit at that point can go several ways: a dose increase if the patient is still below the maximum and tolerating the current dose; a systematic review of the lifestyle and medication factors covered in the checklist above; an evaluation for conditions that reduce GLP-1 responsiveness, such as untreated insulin resistance, thyroid dysfunction, or polycystic ovary syndrome; or a discussion of whether a different medication fits better. None of these decisions should be made without a clinician. Increasing dose without guidance can raise side effect risk without addressing the underlying cause of the stall.
Expectations also deserve revisiting. The STEP 1 trial of Wegovy (semaglutide 2.4 mg) ran for 68 weeks, meaning most of the 14.9 percent average loss accumulated over more than a year of treatment, not a few months. Compounded semaglutide is not FDA-approved, and equivalent long-term trial data do not exist for it. A plateau after four or five months, while disappointing, is often still within the expected progression toward a longer-term result.
When switching GLP-1 medications enters the conversation
Switching to a different GLP-1 receptor agonist is a clinical decision, not a self-directed one, but it is a legitimate option when dose maximization and a thorough lifestyle audit have not produced a sufficient response over an adequate timeframe.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. In the SURMOUNT-1 randomized controlled trial of Zepbound (tirzepatide, FDA-approved for chronic weight management), results summarized in a systematic review published in BMC Endocrine Disorders show that participants on the 15 mg dose achieved a mean body weight reduction of 22.5 percent over 72 weeks. That trial enrolled a different population under different conditions than STEP 1, so a direct comparison across the two trials requires caution. Compounded tirzepatide is not FDA-approved and has not been evaluated in trials equivalent to SURMOUNT-1.
Some individuals show a stronger appetite suppression response to one molecule than the other, and a real-world study published in PMC found meaningful variation in weight loss between semaglutide and tirzepatide across real-world patients. The decision to switch depends on the individual's full medical history, tolerability, access, and out-of-pocket cost. A provider experienced with both medications can make this assessment based on the individual's profile rather than on trial averages alone.